Poolbeg Pharma (LON:POLB) Trading 10.1% Higher – Still a Buy?

Poolbeg Pharma PLC (LON:POLB) shares rose 10.1% on Wednesday . The company traded as high as GBX 5.84 and last traded at GBX 5.55. Approximately 5,824,547 shares changed hands during mid-day trading, an increase of 359% from the average daily volume of 1,268,309 shares. The stock had previously closed at GBX 5.04.

Analysts Set New Price Targets

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a report on Tuesday.

Poolbeg Pharma Trading Up 3.4%

The stock’s fifty day moving average is GBX 4.46 and its 200 day moving average is GBX 4.29. The company has a market capitalization of £40.46 million, a P/E ratio of -6.10 and a beta of 1.78.

Poolbeg Pharma (LON:POLB) last posted its quarterly earnings results on Tuesday, April 28th. The company reported GBX (0.94) EPS for the quarter. On average, analysts expect that Poolbeg Pharma PLC will post -0.68 EPS for the current fiscal year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.